Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More
Shots: Dare to receive up front, $20M as option exercise fee, $310M as commercial milestones, royalties on sales of the product along with access to Bayer’s clinical and market capabilities and remain responsible for development & regulatory activities of Ovaprene Bayer to get exclusive right to commercialize Ovaprene in the US, once approved by the […]Read More
Shots: Vyriad to receive upfront, development and commercial milestone payments based on certain achievements and royalties on sales of products. Regeneron to get an exclusive option to license Vyriad’s Voyager-V1 plus other products and will make equity investment in Vyriad The agreement also includes a P-II clinical study assessing Regeneron’s Libtayo (cemiplimab-rwlc) + Vyriad’s oncolytic […]Read More
Shots: Immatics to get $75M up front and is also eligible to receive ~$505M as option exercise fee for each licensed product including development, regulatory & commercial milestone plus royalties on sales. Immatics may develop TCR-T targets for solid tumors based on its XPRESIDENT technology, will take care of development & validation of the programs […]Read More
Shots: Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will be responsible for all development, regulatory, commercialization activities and its costs In Mar’2010, GSK and Ionis collaborated on RNA therapies for rare and infectious diseases […]Read More
Shots: Pfizer to get exclusive rights for development and commercialization of AnTolRx’s lead immunotherapeutic for T1D. AnTolRx to receive upfront, milestones & royalties on sales Under the June 2016 agreement, Pfizer exercised its option to license AnTolRx’s T1D candidate AnTolRx develops antigen-specific therapies, based on immune tolerance induction, for inflammatory and autoimmune diseases including T1D, […]Read More
Shots: Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s AKCEA-APO(a)-LRx (TQJ230) and will initiate P-III trial for cardiovascular outcomes In Jan,2107 Akcea and its subsidiary Ionis collaborated with Novartis to develop & commercialize AKCEA-APO(a)-LRx […]Read More
Shots: AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights to co-promote ARGX-115 products in the EU and Swiss Economic Area Argenx and AbbVie previously entered into an option and license agreement for ARGX-115 in […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
